Skill Guide
Regulatory Awareness (FDA SaMD) is the professional competency to systematically identify, interpret, and apply the U.S. Food and Drug Administration's (FDA) regulatory requirements and risk-based frameworks specifically to Software as a Medical Device (SaMD) throughout its lifecycle.
Scenario
Your startup has developed a mobile app that uses an algorithm to analyze user-uploaded skin images to provide a risk score for melanoma. You need to determine its regulatory classification and the likely path to market in the U.S.
Scenario
Your company's Class II SaMD, a cloud-based platform for monitoring cardiac arrhythmia data from wearables, has completed prototype development. You need FDA feedback on your clinical evidence plan before initiating a formal 510(k) submission.
Scenario
You are the VP of Regulatory Affairs at a company developing an adaptive SaMD that uses machine learning to refine its diagnostic algorithms over time. You must build a QMS that satisfies 21 CFR 820, addresses the FDA's Good Machine Learning Practice principles, and incorporates a robust cybersecurity management system.
The IMDRF framework is the primary tool for initial risk classification. The FDA TPLC guidance outlines the regulatory expectations from pre-market to post-market. IEC 62304 is the globally recognized standard for software development processes, often required by the FDA, and provides the technical backbone for the QMS.
The classification database is essential for identifying predicates and regulatory pathways. The eSTAR template is the required format for electronic submissions. Project management tools with specialized plugins (e.g., for managing design history files) and dedicated QMS software are critical for maintaining traceability and audit readiness.
Answer Strategy
The interviewer is testing your ability to synthesize classification, pathway, and evidence requirements. Use a structured framework: 1) Define intended use precisely. 2) Apply IMDRF risk categorization (likely Class C/D due to clinical significance). 3) Identify regulatory class (likely II) and pathway (De Novo is probable given novelty). 4) Outline pre-submission plan to get FDA feedback on clinical validation study design. 5) Mention post-market surveillance for this TPLC product. Sample Answer: 'First, we lock down the intended use statement, which is critical for risk. Based on the IMDRF framework, this SaMD provides information to drive clinical management in a serious condition, placing it in a high-risk category, likely Class C or D. I would anticipate a Class II designation and pursue a De Novo classification. My first major step would be filing a Pre-Submission with the FDA to discuss our proposed clinical validation protocol, likely using 24-hour Holter monitor data as a predicate reference method, before we invest in a full study.'
Answer Strategy
This behavioral question assesses proactive risk management and cross-functional leadership. Use the STAR method. Focus on the regulatory consequence (e.g., submission delay, recall risk). Sample Answer: 'During design review of a sepsis prediction SaMD, I noted our cybersecurity threat model was based on an outdated NIST framework and didn't address data-in-transit risks from third-party integrations (Situation). I led a workshop with engineering and security to re-assess the threat landscape using the FDA's premarket cybersecurity guidance (Action). We redesigned the API authentication and logging, which was then validated. This prevented what would have been a major deficiency in our 510(k) submission, avoiding a likely 3-month review hold (Result).'
1 career found
Try a different search term.